The study of Yumeen et al. (2020) supported the clinical implementation of Ruxolitinib as a novel therapy for leukemic CTCL and further enforced the synergistic potential combination of Ruxolitinib with BCL2, HDAC, BET, or proteasome inhibition [68]. Here, BCL2 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.